Cardiovascular disease genetics: A long and winding road

Current Opinion in Lipidology

Volumn 14, Issue 1, 2003, Pages 47-54

  Ordovas, Jose M ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Cardiovascular diseases; Genetics; Nutrigenomics; Nutrition; Pharmacogenomics; Polymorphisms

Indexed keywords

ABC TRANSPORTER; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

CARDIOVASCULAR DISEASE; ENVIRONMENTAL FACTOR; GENETIC POLYMORPHISM; GENETIC RISK; GENETICS; GENOMICS; GENOTYPE; LIPID METABOLISM; METHODOLOGY; NONHUMAN; NUTRITION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

CARDIOVASCULAR DISEASES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MULTIFACTORIAL INHERITANCE; PHENOTYPE;

EID: 0037315050     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200302000-00009     Document Type: Review

References (48)

1. Rees A, Stocks J, Shoulders CC, et al. DNA polymorphism adjacent to human apoprotein A-I gene: relation to hypertriglyceridemia. Lancet 1983; 1:444-446.
2. Lalouel JM, Rohrwasser A. Power and replication in case-control studies. Am J Hypertens 2002; 15:201-205.
3. Dempsey AA, Dzau VJ, Liew CC. Cardiovascular genomics: estimating the total number of genes expressed in the human cardiovascular system. J Mol Cell Cardiol 2001; 33:1879-1886.
4. Hegele RA. SNP judgments and freedom of association [editorial]. Arterioscler Thromb Vasc Biol 2002; 22:1058-1061. This invited editorial brings to our attention many of the issues that we have to consider when interpreting the literature for association studies. Moreover, it points out the proper experimental approaches in order to avoid many of the common pitfalls in this type of study.
5. Almasy L, MacCluer JW. Association studies of vascular phenotypes: how and why? Arterioscler Thromb Vasc Biol 2002; 22:1055-1057.
6. Heistad DD. Genetic association studies. Arterioscler Thromb Vasc Biol 2002; 22:1054.
7. Positive opening for negative results. Nature 2002; 417:890-891.
8. Nakai K, Habano W, Fujita T, et al. Highty multiplexed genotyping of coronary artery disease-associated SNPs using MALDI-TOF mass spectrometry. Hum Mutat 2002; 20:133-138.
9. Fan JB, Chen X, Halushka MK, et al. Parallel genotyping of human SNPs using generic high-density oligonucleotide tag arrays. Genome Res 2000; 10:853-860.
10. Bladbjerg EM, Gram J, Jespersen J, de Maat MP. Internal quality control of PCR-based genotyping methods in research studies and patient diagnostics. Thromb Haemost 2002; 87:812-816.
11. Xu J, Turner A, Little J, et al. Positive results in association studies are associated with departure from Hardy-Weinberg equilibrium: hint for genotyping error? Hum Genet DOI 10.1007/s00439-002-0819-y. We all know about Hardy-Weinberg equilibrium, but sometimes we forget that it exists. This paper describes the many instances in which Hardy-Weinberg equilibrium is not present in case control studies describing significant associations. This is a short paper that should be read by all of us doing this type of study.
12. Lahoz C, Schaefer EJ, Cupples LA, et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 2001; 154:529-537.
13. Attila G, Acarturk E, Eskandari G, et al. Effects of apolipoprotein E genotypes and other risk factors on the development of coronary artery disease in Southern Turkey. Clin Chim Acta 2001; 312:191-196.
14. Wu JH, Lo SK, Wen MS, Kao JT. Characterization of apolipoprotein E genetic variations in Taiwanese: association with coronary heart disease and plasma lipid levels. Hum Biol 2002; 74:25-31.
15. Ewbank DC. Mortality differences by APOE genotype estimated from demographic synthesis. Genet Epidemiol 2002; 22:146-155.
16. Lussier-Cacan S, Bolduc A, Xhignesse M, et al. Impact of alcohol intake on measures of lipid metabolism depends on context defined by gender, body ass index, cigarette smoking, and apolipoprotein E genotype. Arterioscler Thromb Vasc Biol 2002; 22:824-831.
17. Corella D, Tucker K, Lahoz C, et al. Alcohol drinking determines the effect of the APOE locus on LDL-cholesterol concentrations in men: the Framingham Offspring Study. Am J Clin Nutr 2001; 73:736-745.
18. Corella D, Guillen M, Saiz C, et al. Environmental factors modulate the effect of the APOE genetic polymorphism on plasma lipid concentrations: ecogenetic studies in a Mediterranean Spanish population. Metabolism 2001; 50:936-944.
19. Corella D, Guillen M, Saiz C, et al. Associations of LPL and APOC3 gene polymorphisms on plasma lipids in a Mediterranean population: interaction with tobacco smoking and the apoe locus. J Lipid Res 2002; 43:416-427.
20. Ordovas JM, Cupples LA, Corella D, et al. Association of cholesteryl ester transfer protein-TaqlB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol 2000; 20:1323-1329.
21. Brousseau ME, O'Connor Jr JJ, Ordovas JM, et al. Cholesteryl ester transfer protein Taql B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol 2002; 22:1148-1154.
22. Liu S, Schmitz C, Stampfer MJ, et al. A prospective study of TaqlB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. Atherosclerosis 2002; 161:469-474.
23. Dachet C, Poirier O, Cambien F, et al. New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation. Arterioscler Thromb Vasc Biol 2000; 20:507-515.
24. Tai ES, Ordovas JM, Corella D, et al. The TaqlB and -629C>A polymorphisms at the cholesterol ester transfer protein locus: associations with lipid levels in a multi-ethnic population. The 1998 Singapore National Health Survey. Clin Genet (January, 2003, in press).
25. Le Goff W, Guerin M, Nicaud V, et al. A novel cholesteryl ester transfer protein promoter polymorphism (-971G/A) associated with plasma high-density lipoprotein cholesterol levels: interaction with the TaqlB and -629C/A polymorphisms. Atherosclerosis 2002; 161:269-279.
26. Ji J, Herbison CE, Mamotte CD, et al. Hepatic lipase gene -514 C/T potymorphism and premature coronary heart disease. J Cardiovasc Risk 2002; 9:105-113.
27. Ordovas JM, Corella D, Demissie S, et al. Dietary fat intake determines the effect of a common polymorphism in the hepatic lipase gene promoter on HDL metabolism: evidence of a strong dose-effect in this gene-nutrient interaction in the Framingham Study. Circulation 2002; 106:2315-2321. This research demonstrates a strong interaction between this LIPC polymorphism and dietary fat. This could be one of the reasons why some ethnic groups have problems adapting to more westernized dietary habits.
28. Hokanson JE, Cheng S, Snell-Bergeon JK, et al. A common promoter polymorphism in the hepatic lipase gene (LIPC-480C>T) is associated with an increase in coronary calcification in type 1 diabetes. Diabetes 2002; 51:1208-1213.
29. Clee SM, Zwinderman AH, Engert JC, et al. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation 2001; 103:1198-1205.
30. Zwarts KY, Clee SM, Zwinderman AH, et al. ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. Clin Genet 2002; 61:115-125.
31. Trip MD, Smulders YM, Wegman JJ, et al. Frequent mutation in the ABCC6 gene (R1141X) is associated with a strong increase in the prevalence of coronary artery disease. Circulation 2002; 106:773-775. A very interesting observation that further boosts the interest in the ABC family of genes in relation to CVD. Very strong results, but it needs to be replicated in other populations. Moreover, the allele frequency of this polymorphism is low and it may not have a strong effect on the total population risk.
32. Tai ES, Demissie S, Cupples LA, et al. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2002; 22:805-810.
33. Flavell DM, Jamshidi Y, Hawe E, et al. Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 2002; 105:1440-1445.
34. Basso F, Lowe GD, Rumley A, et al. Interleukin-6-174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS). Arterioscler Thromb Vasc Biol 2002; 22:599-604.
35. Maitland-van der Zee AH, Klungel OH, Stricker BH, et al. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 2002; 163:213-222.
36. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002; 51:1256-1262.
37. Eichner JE, Dunn ST, Perveen G, et al. Apolipoprotein E polymorphism and cardiovascular disease: a HuGe review. Am J Epidemiol 2002; 155:487-495.
38. Beisiegel U, Spector AA. Bone: a forgotten organ in lipidology? Curr Opin Lipidol 2002; 13:239-240.
39. Ortlepp JR, Lauscher J, Hoffmann R, et al. The vitamin D receptor gene variant is associated with the prevalence of type 2 diabetes mellitus and coronary artery disease. Diabet Med 2001; 18:842-845.
40. Herrmann SM, Whatling C, Brand E, et al. Polymorphisms of the human matrix gla protein (MGP) gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol 2000; 20:2386-2393.
41. Ogawa S, Urano T, Hosoi T, et al. Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem Biophys Res Commun 1999; 260:122-126.
42. Woods D, Onambele G, Woledge R, et al. Angiotensin-I converting enzyme genotype-dependent benefit from hormone replacement therapy in isometric muscle strength and bone mineral density. J Clin Endocrinol Metab 2001; 86:2200-2204.
43. Herrington DM, Howard TD, Brosnihan KB, et al. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 2002; 105:1879-1882.
44. Herrington DM, Howard TD, Hawkins GA, et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002; 346:967-974.
45. Zitzmann M, Brune M, Kornmann B, et al. The CAG repeat polymorphism in the androgen receptor gene affects bone density and bone metabolism in healthy males. Clin Endocrinol (Oxf) 2001; 55:649-657.
46. Zitzmann M, Brune M, Kornmann B, et al. The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J Clin Endocrinol Metab 2001; 86:4867-4873.
47. Schwahn B, Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am J Pharmacogenomics 2001; 1:189-201.
48. Tiret L, Poirier O, Nicaud V, et al. Heterogeneity of linkage disequilibrium in human genes has implications for association studies of common diseases. Hum Mol Genet 2002; 11:419-429. We need better definition of the alleles that are associated with relevant phenotypes. One way to achieve this is by examining multiple markers per loci and to derive haplotypes. The success of this approach depends on the extent of linkage disequilibrium in the region being considered. These authors have examined this issue in great detail for several CVD candidate genes.